galidesivir

Galidesivir is a small molecule antiviral drug and adenosine nucleoside analog with broad-spectrum activity against RNA viruses, including filoviruses (such as Ebola and Marburg), flaviviruses (such as Zika and Yellow Fever), coronaviruses, arenaviruses, bunyaviruses, paramyxoviruses, orthomyxoviruses, picornaviruses, togaviruses, and phleboviruses. It was originally developed by BioCryst Pharmaceuticals with funding from the U.S. National Institute of Allergy and Infectious Diseases (NIAID). Galidesivir acts by inhibiting viral RNA-dependent RNA polymerase (RdRp): after cellular uptake it is phosphorylated to its active triphosphate form which mimics ATP; this active metabolite is incorporated into viral RNA by RdRp leading to premature chain termination and inhibition of viral replication. The drug has demonstrated efficacy in animal models for several high-consequence viral infections. Clinical development has included phase 1 trials for safety in healthy volunteers and studies in patients with COVID-19[1][2][3][4][5][6][8].

Other names

galidesivirBCX4430 freebaseBCX-4430 freebaseBCX 4430 freebase